Skip to main content
Loading

ProMIS Neurosciences

February 27, 2024
CNS/Neurological
ProMIS Neurosciences
ProMIS Neurosciences (Nasdaq:PMN) is a Cambridge, Massachusetts and Toronto, Ontario-based clinical stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. Using our proprietary target discovery engine, we can predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS).
Testimonials

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP